Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors | Zendy

PerezSomarriba Marta | Zendy; MorenoTejero Maria Luisa | Zendy; Rozas Maria Isabel | Zendy; Pelaez Irene | Zendy; Madero Luis | Zendy; Lassaletta Alvaro | Zendy

Premium

Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors

Author(s) -

PerezSomarriba Marta,

MorenoTejero Maria Luisa,

Rozas Maria Isabel,

Pelaez Irene,

Madero Luis,

Lassaletta Alvaro

Publication year - 2020

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.28089

Subject(s) - medicine , oxaliplatin , gemcitabine , germ cell tumors , paclitaxel , refractory (planetary science) , oncology , chemotherapy , germinoma , germ cell , cancer , biochemistry , chemistry , physics , colorectal cancer , astrobiology , gene

Intracranial germ cell tumors (GCT) account for less than 5% of all central nervous system tumors in children in Western countries. Approximately 40% are nongerminomatous GCT (NGGCT). Despite correct treatment, 16% to 47% of the patients will relapse. There are no standard approaches in case of recurrence, and treatment in this situation remains a challenge. We report three patients diagnosed with relapsed intracranial NGGCT treated with gemcitabine, paclitaxel, and oxaliplatin, in whom the tumor showed a remarkable response with normalization of tumor markers.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research